|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Calquence
gptkb:Imbruvica
|
|
gptkbp:activities
|
gptkb:Bruton_tyrosine_kinase_inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Imbruvica
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
approximately 100%
|
|
gptkbp:contraindication
|
severe hepatic impairment
concomitant use of strong CY P3 A inhibitors
|
|
gptkbp:developed_by
|
gptkb:Pharmacyclics
|
|
gptkbp:dosage_form
|
420 mg once daily
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ibrutinib
|
|
gptkbp:indication
|
first-line treatment for CLL
relapsed or refractory CLL
treatment of MCL
treatment of WM
|
|
gptkbp:ingredients
|
C19 H20 N6 O2 S
|
|
gptkbp:invention
|
2027
patented
|
|
gptkbp:is_atype_of
|
L01 X X32
|
|
gptkbp:is_used_for
|
gptkb:Waldenström's_macroglobulinemia
gptkb:healthcare_organization
mantle cell lymphoma
|
|
gptkbp:lifespan
|
approximately 4-5 hours
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Imbruvica
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
CY P3 A4
|
|
gptkbp:research_areas
|
oncology
hematology
immunology
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
hypertension
bruising
diarrhea
thrombocytopenia
cardiac arrhythmias
hepatotoxicity
increased risk of infection
|
|
gptkbp:treatment
|
gptkb:Rituximab
gptkb:Venetoclax
Obinutuzumab
|
|
gptkbp:type_of
|
936563-96-1
|